Protect your liver naturally from all forms of toxins, from exposure to chemical pollutants and the side effects of prescription drugs, to the overindulgences of rich food and alcohol.
Supports the body in regenerating healthy liver cells to replace those you've lost.
Scientifically proven, patented formula up to 10 times more effective than standard milk thistle formulas.
Heart Health Benefits to You
An in vitro study found that extract of milk thistle protects LDL cholesterol from oxidizing, and is capable of reducing the oxidation of LDL cholesterol by up to 86%.
Because it helps keep blood vessels free and clear of unwanted buildup, taking a silybin supplement, such as Alcohol Reverse ™, may be one of the best ways to maintain heart health.
Milk thistle is the most widely recognized natural remedy for liver health, confirmed by hundreds of clinical studies shown to protect the liver against virtually all types of damage.
Secrets of Eden's Alcohol Reverse ™ provides a highly-absorbable form of milk thistle. Alcohol Reverse ™ can deliver up to 8 to 10 times more of milk thistle's active ingredient to your liver than others, making it a much more effective and economical supplement to address your liver concerns.
Regardless what you feel may be affecting your liver, Alcohol Reverse ™ gives you a natural, effective, convenient, affordable and clinically-proven way to protect and support this vital organ.
In addition to milk thistle's liver health benefits, new research shows that the herb may also play a role in heart health by preventing cholesterol oxidation. At the University of Arkansas, Sunny Wallace and coworkers found that extract of milk thistle, a potent antioxidant, protected LDL cholesterol from oxidizing. The investigators found that one of milk thistle's most active constituents, silybin, was capable of reducing the oxidation of LDL cholesterol by up to 86 percent. Because the oxidation of LDL cholesterol is suspected to play a major role in the development of atherosclerosis and heart disease, taking a silybin supplement, such as Alcohol Reverse Milk Thistle™, may be one of the best ways to maintain heart health.
How Does Secrets of Eden's Alcohol Reverse Milk Thistle™ Work?
The liver is an important organ in regard to your body's energy generation, storage and maintenance. The bio-chemical constituent contained in this product aids the body in detoxification and is a key element in improving liver function.
Order yours today!
Effect of the Bioflavonoid Silymarin on the In Vitro Activity and Expression of Superoxide Dismutase (SOD) Enzyme
Muzes G, Deak G, Lang I, Nekam K, Gergely P, Feher J
2nd Department of Medicine, Semmelweis University, Budapest, Hungary
Superoxide dismutase activity and expression of the erythrocytes and lymphocytes of patients suffering from chronic alcoholic liver disease and those of healthy controls were investigated after in vitro incubation with silymarin. It was concluded that silymarin treatment in a concentration achievable by in vivo treatment (10 micrograms/ml) significantly increased the SOD activity of both the erythrocytes and lymphocytes of patients with liver disease, whereas the SOD expression of the lymphocytes enhanced to a considerable extent. These results indirectly indicate that the scavenger silymarin is able to increase the antioxidant protection of the cells by ameliorating the deleterious effects of free radical reactions.
Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M
Anti-Diabetes Centre, Monfalcone Hospital, Gorizia, Italy
BACKGROUND/AIMS: Several studies have demonstrated that diabetic patients with cirrhosis require insulin treatment because of insulin resistance. As chronic alcoholic liver damage is partly due to the lipoperoxidation of hepatic cell membranes, anti-oxidizing agents may be useful in treating or preventing damage due to free radicals. The aim of this study was to ascertain whether long-term treatment with silymarin is effective in reducing lipoperoxidation and insulin resistance in diabetic patients with cirrhosis.
METHODS: A 12-month open, controlled study was conducted in two well-matched groups of insulin-treated diabetics with alcoholic cirrhosis. One group (n=30) received 600 mg silymarin per day plus standard therapy, while the control group (n=30) received standard therapy alone. The efficacy parameters, measured regularly during the study, included fasting blood glucose levels, mean daily blood glucose levels, daily glucosuria levels, glycosylated hemoglobin (HbA1c) and malondialdehyde levels.
RESULTS: There was a significant decrease (p<0.01) in fasting blood glucose levels, mean daily blood glucose levels, daily glucosuria and HbA1c levels already after 4 months of treatment in the silymarin group. In addition, there was a significant decrease (p<0.01) in fasting insulin levels and mean exogenous insulin requirements in the treated group, while the untreated group showed a significant increase (p<0.05) in fasting insulin levels and a stabilized insulin need. These findings are consistent with the significant decrease (p<0.01) in basal and glucagon-stimulated C-peptide levels in the treated group and the significant increase in both parameters in the control group. Another interesting finding was the significant decrease (p<0.01) in malondialdehyde/levels observed in the treated group.
CONCLUSIONS: These results show that treatment with silymarin may reduce the lipoperoxidation of cell membranes and insulin resistance, significantly decreasing endogenous insulin overproduction and the need for exogenous insulin administration.
Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B
1st Department of Gastroenterology and Hepatology, University of Vienna, Austria
Silymarin, the active principle of the milk thistle Silybum marianum, protects experimental animals against various hepatotoxic substances. To determine the effect of silymarin on the outcome of patients with cirrhosis, a double blind, prospective, randomized study was performed in 170 patients with cirrhosis. 87 patients (alcoholic 46, non-alcoholic 41; 61 male, 26 female; Child A, 47; B, 37; C, 3; mean age 57) received 140 mg silymarin three times daily. 83 patients (alcoholic 45, non-alcoholic 38; 62 male, 21 female; Child A, 42; B, 32; C, 9: mean age 58) received a placebo. Non-compliant patients and patients who failed to come to a control were considered as 'drop outs' and were withdrawn from the study. All patients received the same treatment until the last patient entered had finished 2-years of treatment. The mean observation period was 41 months. There were 10 drop outs in the placebo group and 14 in the treatment group. In the placebo group, 37 (+2 drop outs) patients had died, and in 31 of these, death was related to liver disease. In the treatment group, 24 (+4 drop outs) had died, and in 18 of these, death was related to liver disease. The 4-year survival rate was 58 +/- 9% (S.E.) in silymarin-treated patients and 39 +/- 9% in the placebo group (P = 0.036). Analysis of subgroups indicated that treatment was effective in patients with alcoholic cirrhosis (P = 0.01) and in patients initially rated 'Child A' (P = 0.03). No side effects of drug treatment were observed.
